Three dimensional orbital magnetic resonance T2-mapping in the evaluation of patients with Graves’ ophthalmopathy

Abstract

The clinical application of orbital magnetic resonance (MR) T2-mapping imaging in detecting the disease activity of Graves’ ophthalmopathy (GO), and the predictive values of therapy response to intravenous glucocorticoid (ivGC) were investigated. Approved by the local institutional review board (IRB), 106 consecutive patients with GO were included in this prospective study. All subjects were divided into two groups according to the patients’ clinical activity score (CAS): the CAS positive group (CAS ≥3) or the CAS negative group (CAS <3). T2 relaxation time of extraocular muscles (T2RT; ms) and the areas of four extra-ocular muscles (AEOMs; mm²) were measured by 3D T2-mapping MR sequence before and after methylprednisolone treatment, so as the CAS and some ophthalmic examinations including visual acuity, intra-ocular pressure, eyeball movement, diplopia and proptosis. In addition, 24 healthy volunteers were recruited as the control group. The mean T2RT and AEOMs in CAS positive group were higher than those in CAS negative group. Both CAS positive and negative groups had significantly higher mean T2RT and AEOMs than the control group (P<0.01). There was a positive correlation between T2RT and AEOMs values in GO patients, both of them had a positive correlation with CAS and the ophthalmic examinations. It was concluded that to evaluate the activity of GO, CAS was mostly related to inflammation symptoms of ocular surface, more than that, T2RT and AEOMs were also related to abnormal findings of the ophthalmic examinations including high ocular pressure, impaired eyeball movement, diplopia and proptosis. T2RT and AEOMs can reflex the inflammation state of ocular muscles better. CAS combined with 3D T2-mapping MR imaging could improve the sensitivity of detection of active GO so as the prediction and evaluation of the response to methylprednisolone treatment.

Keywords

Graves’ ophthalmopathy / magnetic resonance / methylprednisolone

References

[1] ZangS, PontoKA, KahalyGJ. Intravenous glucocorticoids for Graves' orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab, 2011, 96(2): 320-332 PMID: 21239515

[2] PetrovicMJ, SarenacT, SreckovicS, et al. . Evaluation of the patients with Grave’s ophthalmopathy after the corticosteroids treatment. Vojnosanit Pregl, 2012, 69(3): 249-252 PMID: 22624411

[3] GongJ, JiangSJ, WangDK, et al. . Association of polymorphisms of rs179247 and rs12101255 in thyroid stimulating hormone receptor intron 1 with an increased risk of Graves' disease: A meta-analysis. J Huazhong Univ Sci Technol [Med Sci], 2016, 36(4): 473-479

[4] BartalenaL, BaldeschilL, DickinsonA, et al. . Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol, 2008, 158(3): 273-285 PMID: 18299459

[5] van GeestRJ, SasimIV, KoppeschaarHP, et al. . Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol, 2008, 158(2): 229-237 PMID: 18230831

[6] UtechCI, KhatibniaU, WinterPF, et al. . MR T2 relaxation time for the assessment of retrobulbar inflamemation in Graves' ophthalmopathy. Thyroid, 1995, 5(3): 185-193 PMID: 7580266

[7] TandaML, PiantanidaE, LiparuloL, et al. . Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center. J Clin Endocrinol Metab, 2013, 98(4): 1443-1449 PMID: 23408569

[8] TachibanaS, MurakamiT, NoguchiH, et al. . Orbital magnetic resonance imaging combined with clinical activity score can improve the sensitivity of detection of disease activity and prediction of response to immuneosuppressive therapy for Graves ophthalmopathy. Endocr J, 2010, 57(10): 853-861 PMID: 20733265

[9] DaumerieC, DuprezT, BoschiA. Long-term multidsciplinary flollow-up of unilateral thyroid-associated orbitopathy. Eur J Intern Med, 2008, 19(7): 531-536 PMID: 19013383

[10] EcksteinAK, PlichtM, LaxH, et al. . Thyrotropin receptor autoantibodies are independent fisk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab, 2006, 91(9): 3464-3470 PMID: 16835285

[11] EnzmannDR, DonaldsonSS, KrissJP. Appearance of Graves' disease on orbital computed tomography. J Comput Assist Tomogr, 1979, 3(6): 815-819 PMID: 583152

[12] JiangH, WangZ, XianJ, et al. . Evaluation of rectus extraocular muscles using contrast-enhanced MR imaging in patients with Graves ophthalmopathy for assessment of disease activity. Acta Radiol, 2012, 53(1): 87-94 PMID: 22184678